Zacks Research Issues Negative Outlook for Novartis Earnings

Key Points

• Zacks Research lowered its Novartis Q1 2028 EPS forecast to $2.54 from $2.55 and projects FY2028 EPS of $10.69; the current full-year consensus is $8.87.
• Novartis recently reported quarterly EPS of $2.41 on revenue of $14.95 billion, with a 23.29% net margin and 38.56% return on equity.
• Analyst sentiment is mixed, with six Buy ratings and ten Holds, resulting in an overall “Hold” consensus and an average price target of $153.00.

Novartis AG (NYSE:NVS - Free Report) - Zacks Research cut their Q1 2028 earnings per share estimates for shares of Novartis in a report issued on Friday, September 25th. Zacks Research analyst Team now forecasts that the company will post earnings of $2.54 per share for the quarter, down from their previous forecast of $2.55. The consensus estimate for Novartis' current full-year earnings is $8.87 per share. Zacks Research also issued estimates for Novartis' FY2028 earnings at $10.69 EPS.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The firm had revenue of $14.95 billion during the quarter.

Several other equities research analysts have also recently commented on the company. Citigroup restated a "buy" rating on shares of Novartis in a research note on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft downgraded shares of Novartis from a "buy" rating to a "hold" rating in a research report on Tuesday, September 8th. Royal Bank Of Canada initiated coverage on shares of Novartis in a report on Tuesday, September 8th. They issued a "sector perform" rating on the stock. HSBC raised shares of Novartis from a "reduce" rating to a "hold" rating and increased their price target for the stock from $123.00 to $136.00 in a report on Thursday, September 10th. Finally, Weiss Ratings reaffirmed a "buy (b)" rating on shares of Novartis in a report on Friday, July 24th. Six investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, Novartis has an average rating of "Hold" and a consensus target price of $153.00.

Novartis Trading Up 1.0%

Shares of NVS stock opened at $146.95 on Tuesday. The company has a market capitalization of $280.40 billion, a P/E ratio of 22.16, a price-to-earnings-growth ratio of 2.81 and a beta of 0.45. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The business's 50 day moving average is $151.62 and its two-hundred day moving average is $151.15. Novartis has a twelve month low of $121.57 and a twelve month high of $170.46.

Institutional Trading of Novartis

Several large investors have recently bought and sold shares of NVS. QRG Capital Management Inc. increased its position in shares of Novartis by 9.0% in the second quarter. QRG Capital Management Inc. now owns 164,478 shares of the company's stock valued at $25,777,000 after buying an additional 13,634 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in shares of Novartis by 3.9% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 19,022 shares of the company's stock worth $2,981,000 after buying an additional 713 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Novartis by 0.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,330,979 shares of the company's stock worth $365,308,000 after buying an additional 19,595 shares in the last quarter. Silicon Valley Capital Partners grew its stake in Novartis by 519.4% in the 2nd quarter. Silicon Valley Capital Partners now owns 192 shares of the company's stock valued at $30,000 after acquiring an additional 161 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new position in Novartis during the 2nd quarter valued at about $4,529,000. Institutional investors and hedge funds own 13.12% of the company's stock.

Novartis Company Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company's research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.